Genmab a potential target for GSK
This article was originally published in Scrip
Executive Summary
Genmab could become a buyout target for GlaxoSmithKline, some analysts speculate, after disappointing results of their co-development drug Arzerra (ofatumumab) in a pivotal Phase III trial in refractory follicular non-Hodgkin's lymphoma (NHL).